PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50125C00017Development of cd388 as a long-lasting — Cidara Therapeutics Inc

Cidara Therapeutics Inc holds $58.1M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Cidara Therapeutics Inc

Recipient

Sep 29, 2027

PoP end

$58.1M

Obligated

541714

NAICS

AN14

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Cidara Therapeutics Inc — $90

Contract facts

NONE

Contract number75A50125C00017

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentCidara Therapeutics Inc

UEIFKP3JZ9RUNY9

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN14

Place of performanceSAN DIEGO, CA

PoP end (current)Sep 29, 2027

PoP end (w/ options)Jul 3, 2030

Obligated$58.1M

DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED… is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Cidara Therapeutics Inc. Estimated value $58.1M ($58.1M obligated). Current period of performance ends Sep 29, 2027 (potential Jul 3, 2030). Last award drew 1 bidder. Place of performance: SAN DIEGO, CA.

DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA

Recompete timing

Public

● Expiring in 387 days

Current PoP ends Sep 29, 2027 (387 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Cidara Therapeutics Inc — $58.1M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$58.1M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50125C00017?

75A50125C00017 (Development of cd388 as a long-lasting) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $58.1M, currently held by Cidara Therapeutics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50125C00017?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50125C00017 to Cidara Therapeutics Inc.

Who is the incumbent on 75A50125C00017?

Cidara Therapeutics Inc is the incumbent with $58.1M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does Cidara Therapeutics Inc’s 75A50125C00017 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50125C00017 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jun 2, 2026